Jung Ju-Yang, Bae Chang-Bum, Suh Chang-Hee
Ajou University School of Medicine, Department of Rheumatology , 164 Worldcup-ro, Yeongtong-gu, Suwon 443-380 , Korea.
Expert Opin Med Diagn. 2013 Nov;7(6):601-13. doi: 10.1517/17530059.2013.846323. Epub 2013 Oct 8.
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with heterogeneous manifestations. Of particular importance for clinicians are the precise assessment of disease activity and the ability to make appropriate therapeutic decisions. Therefore, interest has increased in biomarkers that can be measured as indicators of pathogenic processes, disease activity and response to management.
This article introduces well-studied, as well as newly discovered, biomarkers related to SLE, divided into categories for diagnosis, disease activity and organ involvement.
The lack of reliable biomarkers for lupus hampers the assessment of disease activity and impedes the evaluation of treatment response. Although many reports of lupus biomarkers have been published, few longitudinal and interventional studies have validated the utility of any biomarker for monitoring disease activity. Consortiums of investigators will certainly help in recruiting sufficient number of patients and facilitating the development of standardized assays. Moreover, owing to the multifactorial nature of lupus, a multiplexed approach will clearly be essential. Another promising approach is the use of high-throughput technology, including DNA and antibody microarrays, flow cytometry and proteomic techniques.
系统性红斑狼疮（SLE）是一种临床表现多样的系统性自身免疫性疾病。对于临床医生而言，精确评估疾病活动度以及做出恰当治疗决策的能力尤为重要。因此，能够作为致病过程、疾病活动度及治疗反应指标进行测量的生物标志物受到了更多关注。
本文介绍了与系统性红斑狼疮相关的、经过充分研究以及新发现的生物标志物，分为诊断、疾病活动度和器官受累等类别。
缺乏可靠的狼疮生物标志物阻碍了疾病活动度的评估，并妨碍了对治疗反应的评价。尽管已经发表了许多关于狼疮生物标志物的报告，但很少有纵向和干预性研究验证任何生物标志物在监测疾病活动度方面的效用。研究团队无疑将有助于招募足够数量的患者，并促进标准化检测方法的开发。此外，由于狼疮的多因素性质，采用多重检测方法显然至关重要。另一种有前景的方法是使用高通量技术，包括DNA和抗体微阵列、流式细胞术和蛋白质组学技术。
